联系客服

300181 深市 佐力药业


首页 公告 佐力药业:2020年度财务决算报告

佐力药业:2020年度财务决算报告

公告日期:2021-04-13

佐力药业:2020年度财务决算报告 PDF查看PDF原文

            浙江佐力药业股份有限公司

              2020 年度财务决算报告

      浙江佐力药业股份有限公司(以下简称“公司”)经中汇会计师事务所(特
  殊普通合伙)(以下简称“中汇会计师事务所”)审计,对公司 2020 年度财务报
  告出具了标准无保留意见的审计报告。中汇会计师事务所经审计认为,公司财务
  报表已经按企业会计准则的规定编制,在所有重大方面公允反映了公司 2020 年
  12 月 31 日的财务状况以及 2020 年度的经营成果和现金流量。现将公司 2020 年
  度财务决算的相关内容报告如下:

      一、2020 年度主要会计数据和财务指标

                                                                        单位:元

                            2020 年        2019 年      本年比上年    2018 年

                                                            增减

营业收入(元)          1,090,878,169.19    911,163,975.83    19.72%  730,262,647.14

归属于上市公司股东的净    88,801,777.68    25,592,842.38    246.98%    20,751,769.25
利润(元)
归属于上市公司股东的扣

除非经常性损益的净利润    83,868,492.07    16,693,115.81    402.41%    -5,478,088.07
(元)

经营活动产生的现金流量    279,691,036.27    128,942,614.45    116.91%    78,284,593.74
净额(元)

基本每股收益(元/股)            0.1459          0.0421    246.56%          0.0341

稀释每股收益(元/股)            0.1459          0.0421    246.56%          0.0341

加权平均净资产收益率            6.59%            1.94%      4.65%          1.55%

                          2020 年末      2019 年末    本年末比上    2018 年末

                                                          年末增减

资产总额(元)          2,469,876,379.74  2,050,645,692.02    20.44%  2,113,803,493.39

归属于上市公司股东的净  1,602,812,556.70  1,310,354,170.19    22.32%  1,291,564,348.15
资产(元)

      二、报告期内归属于上市公司股东的权益变动情况

                                                                        单位:元

 项目        股本        资本公积    其他综合收益    盈余公积    未分配利润    所有者权益合计

上年期末

          608,624,848.00  340,278,919.44  41,886,967.50  63,298,194.82  256,265,240.43  1,310,354,170.19
余额
本年期初

          608,624,848.00  340,278,919.44  41,886,967.50  63,298,194.82  256,265,240.43  1,310,354,170.19
余额
本期

              0          196,487.78    215,632,618.01    690,481.68    75,938,799.04    292,458,386.51
增减
本年期末

          608,624,848.00  340,475,407.22  257,519,585.51  63,988,676.50  332,204,039.47  1,602,812,556.70
余额

            三、报告期内主要财务数据大幅变动的情况及原因

            (一)资产负债表中涉及变动情况

                                                                            单位:元

                        2020 年末              2020 年初        比重

                      金额      占总资    金额      占总资  增减      重大变动说明

                                产比例                产比例

        货币资金    253,745,846.42 10.27%  138,413,844.53  6.75%  3.52% 主要系本期经营活动现

                                                                      金流入增加所致

        应收账款    271,859,915.36 11.01%  249,736,863.09  12.18%  -1.17%

        存货        201,441,315.80  8.16%  201,267,597.01  9.81%  -1.65%

        长期股权      1,656,015.93  0.07%    2,101,128.74  0.10%  -0.03%

        投资

                                                                      主要系对科济药业的其

        其他权益    461,342,309.13 18.68%  226,075,000.00  11.02%  7.66% 他权益工具投资按公允

        工具投资

                                                                      价值重新计量所致

                                                                      主要系待处置君康合

        其他流动    132,854,919.92  5.38%    4,008,388.20  0.20%  5.18% 伙、郡健合伙份额重新

        资产

                                                                      列报

        固定资产    749,195,651.75 30.33%  726,943,585.71  35.45%  -5.12%


                                                              主要系公司年产 400 吨
在建工程      896,581.92  0.04%  72,074,445.23  3.51%  -3.47% 乌灵菌粉生产线建设项
                                                              目达到预定可使用状态
                                                              转固所致

短期借款    302,849,294.47 12.26%  216,818,708.33  10.57%  1.69% 主要系改善公司筹资的
                                                              期限结构

                                                              主要系归还了长期借款
长期借款    30,047,895.87  1.22%  88,134,253.53  4.30%  -3.08% 及对部分一年内到期的
                                                              长期借款重分类所致

                                                              主要系本期收到以前年
其他应收      5,898,615.00  0.24%  27,497,575.77  1.34%  -1.10% 度处置长期资产及子公


                                                              司的应收款项所致

    (二)费用情况

                                                                        单位:元

                2020 年        2019 年        同比增减        重大变动说明

                                                          主要系本期乌灵系列、百令
 销售费用    517,609,852.80      446,463,583.36      15.94% 系列及中药配方颗粒剂销售
                                                          收入增长而相应的市场投入
                                                          增加所致。

 管理费用    83,560,821.54      81,189,065.72      2.92%

 财务费用    15,401,110.20      17,543,670.48    -12.21%

 研发费用    30,386,918.42      27,157,823.20      11.89%

    (三)现金流量表中涉及变动情况

                                                                        单位:元

            项目                  本期数            上期数        增减幅度(%)

 经营活动现金流入小计            1,255,008,587.53        976,088,617,16        28.58%

经营活动现金
[点击查看PDF原文]